

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 January 2003 (16.01.2003)

PCT

(10) International Publication Number
WO 03/004059 A1

- (51) International Patent Classification⁷: A61K 47/14, 31/7048, A61P 33/10
- (21) International Application Number: PCT/AU02/00867
- (22) International Filing Date: 1 July 2002 (01.07.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PR 6105 4 July 2001 (04.07.2001) AU
- (71) Applicant (for all designated States except US): SMART DRUG SYSTEMS INC [US/US]; 181 South Broad Street, Suite 102, Pawcatuck, CT 06379 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MARTINOD, Serge, R. [US/US]; 37 Skyline Drive, Groton, CT 06340-5427 (US). BRANDON, Malcolm [AU/AU]; 8 Tanami Court, Bulleen, VIC 3105 (AU).
- (74) Agent: FREEHILLS CARTER SMITH BEADLE; Level 43, 101 Collins Street, Melbourne, VIC 3000 (AU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/004059 A1

(54) Title: TREATMENT OF PARASITIC DISEASE

(57) Abstract: Use of an anti-parasitic agent in a sustained release form in the treatment of ectoparasitic infections.

TREATMENT OF PARASITIC DISEASE

The present invention relates to a method of treatment of parasitic diseases, including external (ecto-) and internal (endo-) parasites and to a sustained release pharmaceutical composition for such treatment. More 5 specifically, the present invention relates to the use of a sustained release pharmaceutical composition which provides a significant increase in the bio-availability of the pharmaceutical composition with a corresponding increase in the blood levels of the pharmaceutical agent.

Parasitic diseases are of particular concern in domestic and farm animals, 10 in particular cattle, sheep, pigs, dogs, cats, rats, mice, birds and fish. Numerous forms of treatment are known including oral tablets, pour-ons, injectables and the like. However, many of the known treatments suffer from the fact that exposure to an infected environment leads to a high level of re-infection as soon as the effect of the treatment wears off.

15 In the case of pour-on formulations, their use is characterised by high levels of wastage and pollution of the environment with often toxic chemicals.

For example, a particularly useful anti-parasitic agent is ivermectin. This product first became available in an injectable formulation, and later as a pour-on. However, both methods of drug administration require animals to be treated on 20 several occasions. For example, once at the start of grazing and again about six weeks later. In addition, drug levels in the blood are high immediately after administration, but drop substantially after about four weeks. This often results in re-infection developing within six to eight weeks after the second treatment.

However, in addition, the use of ivermectin is not indicated for the treatment 25 of parasitic infestations for smaller animals with the exception of heartworm, particularly cats and dogs, as the high levels required using the conventional methods of application named above to generate protection may be toxic, even lethal, to such animals.

Accordingly, where a disease indication requires the achievement of a high threshold blood plasma level and/or requires the delivery of multiple pharmaceuticals and/or requires sustained release to be continued over an extended period at high levels, the drug delivery systems known in the prior art
5 generally exhibit insufficient drug carrying capacity.

Whilst it is theoretically possible to increase the amount of active delivered by increasing the size of the drug delivery systems in one or more dimensions (e.g. length or diameter), this may not achieve the anticipated result, e.g. as this may lead to "dose dumping" which may be harmful or even lethal to the animal to
10 be treated. Alternatively the large size of the apparatus may prevent its use even with relatively large animals, in particular cattle.

For example, such drug delivery implants may be placed subcutaneously in the ear of an animal. This may be physically impossible where the size of the implant becomes too large.

15 Further, it has been found that use of multiple implants does not provide the required threshold blood level of pharmaceutical required to successfully treat the disease indication to be treated. This also is limiting due to the total bulk of the implants used.

It is, accordingly, an object of the present invention to overcome or at least
20 alleviate one or more of the difficulties and deficiencies related to the prior art.

Accordingly, in a first aspect, the present invention provides for use of an anti-parasitic agent in a sustained release form, in the treatment of external parasites.

The anti-parasitic agent may include a macrocyclic lactone, for example
25 ivermectin, moxidectin, eprinomectin, doramectin, an insect growth regulator, or mixtures thereof.

The anti-parasitic agent may be used in the treatment of any and all animals, including domestic and farm animals, including sheep, cattle, horses,

pigs, goats, dogs, cats, ferrets, rodents, including mice and rats, birds, including chicken, geese and turkeys, marsupials, fish, primates and reptiles.

It has surprisingly been found that use of an anti-parasitic agent, e.g. ivermectin, in a sustained release (i.e. solid) form permits the achievement of 5 ectoparasitic, and optionally endoparasitic protection to animals, without reaching harmful or toxic levels.

Accordingly, in a further aspect of the present invention, there is provided a method of treating parasitic diseases in animals, which method includes administering to an animal a prophylactically or therapeutically effective, but 10 non-toxic, amount of an anti-parasitic agent in a sustained release form.

The anti-parasitic agent may include a macrocyclic lactone, as described above.

Preferably the parasitic disease to be treated may include an external (ecto-) parasitic infestation, for example fleas, ticks, mites, lice and the like.

15 In a particularly preferred form, the method may provide for the concomitant treatment of internal (endo-) parasitic infestations including worms, e.g. heartworm.

Accordingly, in a more preferred aspect, the present invention provides for use of an anti-parasitic agent in a sustained release form in the concomitant 20 treatment of external and internal parasites.

For example, where the anti-parasitic agent is ivermectin, the present invention provides for the concomitant treatment of internal parasites (including worms, e.g. heartworm, roundworms) and external parasites (including fleas, ticks and mites) in animals, including domestic and farm animals including in particular 25 cats and dogs.

The anti-parasitic agent may be provided in a sustained release delivery apparatus including a plurality of sustained release mini-implants or pellets;

- each mini implant or pellet including
an anti-parasitic composition including
at least one anti-parasitic agent;
a carrier therefor; and optionally
5 a sustained release support material; the anti-parasitic
composition carried in or on the sustained release support material,
when present;
each implant being of insufficient size individually to provide a
predetermined desired threshold blood level of anti-parasitic active for treatment of
10 a selected disease indication.

Preferably each mini-implant includes
a pharmaceutical active-containing inner layer; and
a water-impermeable outer layer.

More preferably each mini-implant takes the form of an extruded rod
15 bearing a water-impermeable coating thereover.

In a further preferred form the plurality of sustained release mini-implants or
pellets in combination may provide a blood level of pharmaceutical active at least
equal to a predetermined threshold for an extended period, e.g. of approximately 1
to 24, preferably 1 to 4 weeks for ivermectin active.

20 In one embodiment, the plurality of sustained release mini-implants or
pellets may be of two or more different sizes and provides for the concomitant
treatment of ectoparasites and endoparasites.

The mini-implants or pellets may be provided in a first size which provides a
blood level of pharmaceutical active of approximately 1.25 to 3 times the desired
25 threshold blood level for an extended, though relatively short, period, e.g. of
approximately 1 to 4 weeks, and in a second size which provides a blood level at
or near the desired threshold blood level over a longer time period, e.g. of
approximately 4 to 52 weeks.

In a particular preferred form, the present invention provides a method of treating fleas in animals, which method includes

administering to an animal a prophylactically or therapeutically effective, but non-toxic amount of an anti-parasitic agent, preferably a macrocyclic lactone, in a
5 sustained release form.

The animals to be treated preferably include cats, dogs, ferrets and rodents.

The sustained release form utilised in the present invention may include a sustained release apparatus.

Accordingly the present invention in this form provides a method for the
10 therapeutic or prophylactic treatment of a parasitic condition in an animal (including a human) requiring such treatment, which method includes administering to the animal a sustained release delivery apparatus including a plurality of sustained release mini-implants or pellets;

each mini implant or pellet including
15 an anti-parasitic composition including
at least one anti-parasitic agent;
a carrier therefor; and optionally
a sustained release support material; the anti-parasitic
composition carried in or on the sustained release support material,
20 when present;

each implant being of insufficient size individually to provide a predetermined desired threshold blood level of anti-parasitic active for treatment of a selected disease indication; and

25 administering the sustained release delivery apparatus to the animal to be treated.

Applicants have surprisingly found that the threshold blood level of the anti-parasitic agent required to treat external, and optionally internal parasites, may be achieved utilising a series of mini-implants or pellets which individually may be of insufficient or no value in treating the disease.

Preferably the sustained release apparatus may provide approximately zero order release of pharmaceutical active.

- In a further preferred form, each mini-implant includes
a pharmaceutical active-containing inner layer; and
5 a water impermeable outer layer.

More preferably, each mini-implant takes the form of an extruded rod bearing a water-impermeable coating thereover.

- In a particularly preferred embodiment, the mini-implants or pellets are provided in at least two different sizes and provides for the concomitant treatment
10 of ectoparasites and endoparasites.

- The mini-implants or pellets are provided
in a first size which provides a blood level of pharmaceutical active of approximately 1.25 to 3 times the desired threshold blood level for a first relatively short time period; and
15 in a second size which provides a blood level of pharmaceutical active at or near the desired threshold blood level for a second longer time period.

- In a still further preferred form, the sustained release apparatus may be provided as a sustained release kit. In this embodiment, the method according to the present invention includes
20 providing a sustained release kit including
a plurality of sustained release mini implants or pellets packaged for delivery in a single treatment;
each mini-implant or pellet including
an anti-parasitic composition including
25 at least one pharmaceutically active component including an anti-parasitic agent;
a carrier therefor; and optionally
a sustained release support material; the anti-parasitic composition carried in or on the sustained release support

- material;
- each implant being of insufficient size individually to provide a predetermined desired threshold blood level of anti-parasitic agent for treatment of external parasites; and
- 5 administering the mini implants or pellets in a single treatment.

Optionally the sustained release kit further includes a sustained release delivery apparatus.

- For example, in veterinary applications, an injector instrument for subcutaneous delivery of standard size pellets may be used as the sustained
- 10 release delivery apparatus.

The multiple mini-pellets may be provided in a single cartridge for use in a standard injector instrument which in turn disperse as individual mini-pellets within the body of the animal to be treated.

- In a further preferred form of the present invention, the plurality of sustained
- 15 release implants may be provided in a biodegradable sheath. The biodegradable sheath may be formed of a water-soluble material.

The water-soluble material utilised in the biodegradable sheath may be selected from one or more of the water-soluble substances described below.

- Each sustained release mini-pellet according to the present invention may
- 20 be biodegradable.

Each sustained release mini-pellet according to the present invention may be of the covered rod or matrix type. A rod-like shape is preferred.

- For example each sustained release mini-pellet may be approximately 0.1 to 0.5 times, preferably approximately 0.20 to 0.25 times, the length of a single rod
- 25 shaped implant, capable of providing the desired threshold blood level of anti-parasitic agent.

For example, in veterinary applications, a typical cattle implant is the product sold under the trade designation "Revalor", and containing as pharmaceutical actives trembolone acetate and estradiol. This implant has the dimensions 4 mm x 4 mm. The equivalent implant according to the present
5 invention may have dimensions of 4 mm x 2 mm.

The sustained release delivery apparatus may take the form of a covered rod or dispersed matrix structure. Such a multi mini-pellet system permits the treatment of diseases over an extended period with pharmaceutically active components which have heretofore not been applicable to such diseases as it has
10 not been possible to achieve the required threshold blood plasma levels to be efficacious and to maintain those blood levels over an extended period of time.

Preferably the sustained release delivery apparatus may provide approximately zero order release of pharmaceutical active.

For example, in veterinary applications, the pharmaceutically active
15 component ivermectin is a mixture of not less than 90% ivermectin H₂B_{1a} and not more than 5% ivermectin H₂B_{1b} having the respective molecular weights 875.10 and 861.07. Ivermectin is a potent macrocyclic lactone disaccharide antiparasitic agent used to prevent and treat parasite infestations in animals. The compound has activity against both internal and external parasites as well as being effective
20 against arthropods, insects, nematodes, filarioidea, platyhelminths and protozoa.

The sustained release support material may take the form of a support matrix or rod, preferably a covered rod structure.

The sustained release support material may be formed from a biodegradable or biocompatible material, preferably a biocompatible hydrophobic
25 material. The biocompatible material may be selected from the group consisting of polyesters, polyamino acids, silicones, ethylene-vinyl acetate copolymers and polyvinyl alcohols. Preferably the sustained release support material is a silicone material. A silicone rod is preferred. The silicone material may be a porous silicon or Biosilicon material, for example as described in International patent application

PCT/GB99/01185, the entire disclosure of which is incorporated herein by reference. A mesoporous, microporous or polycrystalline silicon or mixtures thereof may be used.

- Biodegradable polymers that may be employed in the present invention
- 5 may be exemplified by, but not limited to, polyesters such as poly(lactic acid-glycolic acid) copolymers (PLGA), etc. and by hydrophobic polyamino acids such as polyarainin, polyleucine, polyanhydride, poly(glycerol-sebacate)(PGS), Biopol and the like. The hydrophobic polyamino acids mean polymers prepared from hydrophobic amino acids.
- 10 Nonbiodegradable polymers that may be employed in the present invention may be exemplified by, but not limited to, silicones, polytetrafluoroethylenes, polyethylenes, polypropylenes, polyurethanes, polyacrylates, polymethacrylates such as polymethylmethacrylates, etc., ethylene-vinyl acetate copolymers, and others. More preferably a silicone elastomer as described in copending Australian
- 15 provisional patent application PR7614, to applicants (the entire disclosure of which is incorporated herein by reference), may be used.

- The anti-parasitic composition, as described above may, in a preferred embodiment, further include at least one pharmaceutically active component. The pharmaceutically active component may be exemplified by, but not limited to, one
- 20 or more selected from the group consisting of:

Analgesics	Anti-arthritis
Anti-convulsivants	Anti-fungals
Anti-histamine	Anti-infectives
Anti-inflammatories	Anti-microbials
Antiprotozoals	Antiviral pharmaceuticals
Contraceptives	Growth promoters
Hematinics	Hemostatics
Hormones and analogs	Immunostimulants
Minerals	Muscle relaxants
Vaccines and adjuvants	Vitamins

The pharmaceutically active component may include a water-insoluble pharmaceutical, a water-soluble pharmaceutical or mixtures thereof.

The water-soluble pharmaceutical actives useful in the sustained release delivery apparatus according to the present invention include such drugs as peptides, proteins, glycoproteins, polysaccharides, and nucleic acids.

The present invention is particularly appropriate for delivery of pharmaceuticals, in addition to parasitic agents, that are very active even in extremely small quantities and whose sustained long-term administration is sought. When used in substantially increased quantities, such pharmaceuticals may be applied to disease indications heretofore untreatable over an extended period. The pharmaceuticals may be exemplified by, but not limited to, one or more selected from the group consisting of cytokines (eg. interferons and interleukins), hematopoietic factors (eg. colony-stimulating factors and erythropoietin), hormones (eg. growth hormone, growth hormone releasing factor, calcitonin, leuteinizing hormone, leuteinizing hormone releasing hormone, and insulin), growth factors (eg. somatotropin, nerve growth factor), neurotrophic factors, fibroblast growth factor, and hepatocyte proliferation factor; cell adhesion factors; immunosuppressants; enzymes (eg. asparaginase, superoxide dismutase, tissue plasminogen activating factor, urokinase, and prourokinase), blood coagulating factors (eg. blood coagulating factor VIII), proteins involved in bone metabolism (eg. BMP (bone morphogenetic protein)), and antibodies.

The interferons may include alpha, beta, gamma, or any other interferons or any combination thereof. Likewise, the interleukin may be IL-1, IL-2, IL-3, or any others, and the colony-stimulating factor may be multi-CSF (multipotential CSF), GM-CSF (granulocyte-macrophage CSF), G-CSF (granulocyte CSF), M-CSF (macrophage CSF), or any others.

Vaccines are particularly preferred. The vaccines useful in the sustained release delivery apparatus according to the present invention may be exemplified

by, but not limited to, one or more selected from the group consisting of

Adenovirus	Anthrax
BCG	Chlamydia
Cholera	Circovirus
Classical swine fever	Coronavirus
Diphtheria-Tetanus (DT for children)	Diphtheria-Tetanus (tD for adults)
Distemper virus	DTaP
DTP	E coli
Eimeria (coccidosis)	Feline immunodeficiency virus
Feline leukemia virus	Foot and mouth disease
Hemophilus	Hepatitis A
Hepatitis B	Hepatitis B/Hib
Herpes virus	Hib
Influenza	Japanese Encephalitis
Lyme disease	Measles
Measles-Rubella	Meningococcal
MMR	Mumps
Mycoplasma	Para influenza virus
Parvovirus	Pasteurella
Pertussis	Pestivirus
Plague	Pneumococcal
Polio (IPV)	Polio (OPV)
Pseudorabies	Rabies
Respiratory syncitial virus	Rotavirus
Rubella	Salmonella
Tetanus	Typhoid
Varicella	Yellow Fever

For example, in veterinary applications for control of parasitic infections, a combination of ivermectin and praziquantel or a combination of zeranol and
5 trembolone may be used.

As stated above, the anti-parasitic composition according to the present invention further includes a carrier for the anti-parasitic agent component.

The carrier may be selected to permit release of the pharmaceutically active component over an extended period of time from the composition.

- 5 The carrier may include a water-soluble substance.

A water-soluble substance is a substance which plays a role of controlling infiltration of water into the inside of the drug dispersion. There is no restriction in terms of the water-soluble substance so long as it is in a solid state (as a form of a preparation) at the body temperature of an animal or human being to which it is to 10 be administered, and a physiologically acceptable, water-soluble substance.

One water-soluble substance, or a combination of two or more water-soluble substances may be used. The water-soluble substance specifically may be selected from one or more of the group consisting of synthetic polymers (eg. polyethylene glycol, polyethylene polypropylene glycol), sugars (eg. sucrose, 15 mannitol, glucose, sodium chondroitin sulfate), polysaccharides (e.g. dextran), amino acids (eg. glycine and alanine), mineral salts (eg. sodium chloride), organic salts (eg. sodium citrate) and proteins (eg. gelatin and collagen and mixtures thereof).

In addition, when the water-soluble substance is an amphipathic substance, 20 which dissolves in both an organic solvent and water, it has an effect of controlling the release of, for example, a lipophilic drug by altering the solubility thereof. An amphipathic substance includes, but not limited to, polyethylene glycol or a derivative thereof, polyoxyethylene polyoxypropylene glycol or a derivative thereof, fatty acid ester and sodium alkylsulfate of sugars, and more specifically, 25 polyethylene glycol, polyoxy stearate 40, polyoxyethylene[196]polyoxypropylene-[67]glycol, polyoxyethylene[105]polyoxypropylene[5]glycol, polyoxyethylene-[160]polyoxypropylene[30]glycol, sucrose esters of fatty acids, sodium lauryl sulfate, sodium oleate, sodium desoxycholic acid (sodium deoxycholic acid (DCA)) of which mean molecular weights are more than 1500.

Polyoxyethylene polyoxypropyleneglycol, sucrose, or a mixture of sucrose and sodium deoxycholic acid (DCA) are preferred.

In addition, the water-soluble substance may include a substance which is water-soluble and has any activity in vivo such as low molecular weight drugs, 5 peptides, proteins, glycoproteins, polysaccharides, or an antigenic substance used as vaccines, i.e. water-soluble drugs.

The pharmaceutical carrier may constitute from approximately 5% to 30% by weight, preferably approximately 10% to 20% by weight based on the total weight of the pharmaceutically active composition.

10 Each sustained release implant or mini-pellet may include additional carriers or excipients, lubricants, fillers, plasticisers, binding agent, pigments and stabilising agents.

Suitable fillers may be selected from the group consisting of talc, titanium dioxide, starch, kaolin, cellulose (microcrystalline or powdered) and mixtures 15 thereof.

Suitable binding agents include polyvinyl pyrrolidine, hydroxypropyl cellulose and hydroxypropyl methyl cellulose and mixtures thereof.

The sustained release implant according to the present invention may have a rod-like shape, for example it is selected from circular cylinders, prisms, and 20 elliptical cylinders. When the device is administered using an injector-type instrument, a circular cylindrical device is preferred since the injector body and the injection needle typically have a circular cylindrical shape.

The sustained release implant according to the present invention may be manufactured according to the method described in copending Australian 25 provisional patent application PR7614 referred to above.

The inner layer of the pharmaceutical formulation of the present invention, viewed in right section, may contain two or more layers containing different anti-

parasitic agents and/or pharmaceuticals. These layers may take the form of concentric circles with a single center of gravity or may appear as a plural number of inner layers whose respective centers of gravity lie at different points in the cross section. When the formulation contains more than one inner layer there 5 may be one or more anti-parasitic agents or pharmaceuticals present in the inner layers. For example, the actives may be present such that each layer contains a different active or there is more than one active in one or all of the inner layers.

The size of the sustained release anti-parasitic formulation of the present invention may, in the case of subcutaneous administration, be relatively small, e.g. 10 1/4 to 1/10 normal size. For example using an injector-type instrument, the configuration may be circular cylindrical, and the cross-sectional diameter in the case is preferably 0.2 to 4 mm, the axial length being preferably approximately 0.2 to 30 mm, preferably approximately 0.5 to 15 mm, more preferably approximately 1 to 10 mm.

15 The thickness of the outer layer should be selected as a function of the material properties and the desired release rate. The outer layer thickness is not critical as long as the specified functions of the outer layer are fulfilled. The outer layer thickness is preferably 0.05 mm to 3 mm, more preferably 0.05 mm to 0.25 mm, and even more preferably 0.05 mm to 0.1 mm.

20 Sustained release implants according to the present invention may preferably have a double-layer structure, in order to achieve long-term zero-order release.

Where a double-layer structure is used, the anti-parasitic-containing inner layer and the water-impermeable outer layer may be fabricated separately or 25 simultaneously. A circular cylindrical sustained release apparatus with a single centre of gravity in the device cross section may be fabricated, for example, by the following methods:

- (1) initial fabrication of a rod-shaped inner layer followed by coating the rod with a liquid containing dissolved outer layer material and drying;

- (2) insertion of a separately fabricated inner layer into a tube fabricated from outer layer material; or
- (3) simultaneous extrusion and molding of the inner and outer layers using a nozzle.

5 However, the fabrication method is not limited to these examples. When a water-impermeable outer layer cannot be obtained in a single operation, it will then be necessary, for example, to repeat the outer layer fabrication process until water permeation can be prevented. In any case, the resulting composition is subsequently cut into suitable lengths. Successive cutting yields a sustained
10 release apparatus according to the present invention having both ends open.

An anti-parasitic formulation with an open end at one terminal may be fabricated by dipping one terminal of the anti-parasitic formulation into a solution which dissolves the outer-layer material and drying it, or by covering one terminal end of the anti-parasitic formulation with a cap made from the outer-layer material.
15 In addition, the fabrication may comprise insertion of the inner layer into an outer-layer casing with a closed-end at one terminal, which are separately produced, and also formation of the inner layer in said casing.

In a further aspect of the present invention there is provided a method for the therapeutic or prophylactic treatment of a parasitic condition in an animal
20 (including a human) requiring such treatment, which method includes administering to the animal a sustained release delivery apparatus including a plurality of sustained release mini-implants or pellets;

each implant including
the anti-parasitic composition including
25 at least one anti-parasitic agent; and
a carrier therefor; and optionally
a sustained release support material; and
the anti-parasitic composition carried in or on the sustained release support material, when present;
30 each implant being of insufficient size individually to provide a

predetermined desired threshold blood level of anti-parasitic active for treatment of a selected disease indication.

As stated above, it has been found that the pharmaceutical payload may be increased by the sustained release delivery apparatus according to the present invention when compared to the prior art. Infestations and diseases which were therefore untreatable may now be treated over an extended period of time utilising the apparatus of the present invention. For example, treatment with ivermectin in dogs may result in protection levels, e.g against fleas and endoparasites such as worms for up to an entire season (e.g. three to six months), with protection against heartworm for up to 12 months.

For example, in animals suffering from parasitic infections such as fleas or ticks, the animals may be treated utilising the sustained release delivery apparatus including an anti-parasitic drug such a ivermectin. As stated above, it was not possible to achieve a required blood concentration threshold to permit treatment of such a parasitic disease utilising a sustained release approach as the required blood concentration threshold could not be achieved utilising such a mechanism.

The method of administration may include subcutaneous or intramuscular injection, intradermal injection, intraperitoneal injection, intranasal insertion or indwelling, intrarectal insertion or indwelling, for example as a suppository or utilising oral administration.

The animals to be treated may be selected from the group consisting of sheep, cattle, horses, pigs, goats, dogs, cats, ferrets, rodents, including mice and rats, birds, including chicken, geese and turkeys, marsupials, fish, primates and reptiles.

The method according to the present invention is particularly applicable to larger animals, e.g. cattle, sheep, pigs, dogs, cats and humans where high dosage levels are required to achieve the prerequisite threshold pharmaceutical active blood levels for successful treatment of selected disease and/or parasitic indications.

Preferably, each mini implant takes the form of a compressed tablet or extruded rod bearing a silicone coating thereover.

More preferably each mini implant is approximately 0.1 to 0.5 times the length and/or diameter of a standard full size tablet.

- 5 In a preferred embodiment, the method further includes providing a sustained release kit including
 - a plurality of sustained release mini implants or pellets packaged for delivery in a single treatment;
 - each mini-implant or pellet including
- 10 an anti-parasitic composition including
 - at least one pharmaceutically active component
 - including an anti-parasitic agent;
 - a carrier therefor; and optionally
 - a sustained release support material; the anti-parasitic composition carried in or on the sustained release support material;
- 15 each implant being of insufficient size individually to provide a predetermined desired threshold blood level of anti-parasitic agent for treatment of external parasites; and
- 20 administering the mini implants or pellets in a single treatment.

Preferably the plurality of sustained release mini implants or pellets are provided in a biodegradable sheath and administered as a single cartridge via an injector instrument.

- The present invention will now be more fully described with reference to the
- 25 accompanying examples.. It should be understood, however, that the description following is illustrative only and should not be taken in anyway as a restriction on the generality of the invention described above.

EXAMPLE 1

- A mixture of ivermectin and carrier material in proportions specified in Table 1 below was produced. The obtained solid was milled and passed through a sieve (212 µm). A portion of a powder thus obtained and Silastic™ Medical Grade ETR Elastomer Q7-4750 Component A and Silastic™ Medical Grade ETR Elastomer Q7-4750 component B were mixed to give a drug dispersion component. Silastic™ Medical Grade ETR Elastomer Q7-4750 Component A and Silastic™ Medical Grade ETR Elastomer Q7-4750 Component B were mixed to give a coating layer component. Thus obtained drug dispersion component and coating layer component were molded by extruding from a double extruder which enables them to be molded by extruding so that the drug dispersion is concentrically coated with the coating layer, and was allowed to stand at room temperature to cure, which was cut to obtain the cylindrical preparation 1 (the length of the preparation is 500 mm, the diameter of the preparation is 1.5 mm).
- 15 The cylindrical preparation 1 is then cut into various lengths as shown in Table 1 to provide the sustained release mini-pellets according to the present invention.

Examination 1

- Preparation 1 was subcutaneously administered to dogs, whole blood was collected from the animal via the jugular vein and the dogs periodically challenged with fleas.

Results are shown in Tables 1 and 2.

TABLE 1

Implant	Dose	Total length cm	Length combinations	No. Dogs	Bleed (weeks)		
					0	2	Flea Challenge 2 weeks
30% (80% IVM, 13% DOC, 7% sucrose) 70% silicone					✓	✓	✓
	18.8 mg	4.8 cm	2 x 1.2, 12 x 0.2	3	✓	✓	✓
	9.4 mg	2.4 cm	1 x 1.2, 6 x 0.2	3	✓	✓	✓
	9.4 mg	2.4 cm	2 x 0.6, 6 x 0.2	3	✓	✓	✓
	4.7 mg	1.2 cm	6 x 0.2	3	✓	✓	✓
		0	0	3	✓	✓	✓

All dogs not to be treated with Revolution/ivermectin or any other anti-parasitic

TABLE 2 - (Results at 4 weeks)

Group No.	Sample No.	Breed	Sex	Number of fleas applied	Number of fleas collected at 48 hours after administration	% Reduction in flea burden
1	1	Labrador	F	99	4	75%
	2	Beagle	F	95	8	75%
	3	Labrador	F	82	11	75%
2	4	Labrador	F	98	0	79.5%
	5	Beagle	F	45	18	79.5%
	6	Labrador	F	99	1	79.5%
3	7	Beagle	F	100	17	55.4%
	8	Labrador	F	97	24	55.4%
	9	Labrador	F	96	0	55.4%
4	10	Beagle	M	99	18	67.4%
	11	Labrador	F	97	12	67.4%
	12	Labrador	F	80	0	67.4%
5	13	Beagle	F	80	37	0
	14	Labrador	F	100	23	0
	15	Labrador	F	96	32	0

% Reduction = $\frac{\text{mean count (controls)} - \text{mean count (treated)}}{\text{mean count (controls)}}$ x 100

It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.

- 5 It will also be understood that the term "comprises" (or its grammatical variants) as used in this specification is equivalent to the term "includes" and should not be taken as excluding the presence of other elements or features.

CLAIMS

1. Use of an anti-parasitic agent in a sustained release form in the treatment of ectoparasitic infections.
2. Use according to Claim 1, wherein the anti-parasitic agent includes a macrocyclic lactone or insect growth regulator, or mixtures thereof.
3. Use according to Claim 2, wherein the macrocyclic lactone is selected from one or more of the group consisting of ivermectin, moxidectin, eprinomectin and doramectin.
4. Use according to Claim 1, wherein the anti-parasitic agent provides protection to animals against ectoparasitic infections without reaching harmful toxic levels.
5. Use according to Claim 4, wherein the anti-parasitic agent in a sustained release form provides protection concomitantly against ectoparasitic and endoparasitic infections.
- 15 6. Use according to Claim 5, wherein the anti-parasitic agent includes ivermectin and provides for the concomitant treatment of ectoparasites and endoparasites.
7. Use according to Claim 1, wherein the animal to be treated is a domestic or farm animal.
- 20 8. Use according to Claim 1, wherein the animal to be treated is selected from the group consisting of sheep, cattle, horses, pigs, goats, dogs, cats, ferrets, rodents, including mice and rats, birds, including chicken, geese and turkeys, marsupials, fish, primates and reptiles.
9. Use according to Claim 1, wherein the anti-parasitic agent is provided in a sustained release delivery apparatus including a plurality of sustained release mini-implants or pellets;

- each mini implant or pellet including
an anti-parasitic composition including
at least one anti-parasitic agent;
a carrier therefor; and optionally
5 a sustained release support material; the anti-parasitic
composition carried in or on the sustained release support material,
when present;
each implant being of insufficient size individually to provide a
predetermined desired threshold blood level of anti-parasitic active for treatment of
10 a selected disease indication.
10. Use according to Claim 9, wherein each mini-implant includes
an inner pharmaceutical active-containing inner layer; and
a water-impermeable outer layer.
11. Use according to Claim 10, wherein each mini-implant takes the form
15 of an extruded rod bearing a water-impermeable coating thereover.
12. Use according to Claim 9, wherein the mini-implants or pellets are
provided in at least two different sizes and provides for the concomitant treatment
of ectoparasites and endoparasites.
13. Use according to Claim 12, wherein the mini-implants or pellets are
20 provided
in a first size which provides a blood level of pharmaceutical active of
approximately 1.25 to 3 times the desired threshold blood level for a first relatively
short time period; and
in a second size which provides a blood level of pharmaceutical active at or
25 near the desired threshold blood level for a second longer time period.
14. A method of treating parasitic diseases in animals, which method
includes administering to an animal a prophylactically or therapeutically effective,
but non-toxic, amount of an anti-parasitic agent in a sustained release form.

15. A method according to Claim 14, wherein the anti-parasitic agent includes a macrocyclic lactone, or an insect growth regulator, or mixtures thereof.

16. A method according to Claim 15, wherein the macrocyclic lactone is selected from one or more of the group consisting of ivermectin, moxidectin,
5 eprinomectin and doramectin.

17. A method according to Claim 16, wherein the anti-parasitic agent includes ivermectin.

18. A method according to Claim 17, wherein the method provides for the concomitant treatment of ectoparasitic and endoparasitic infections.

10 19. A method of treating fleas in animals, which method includes administering to an animal a prophylactically or therapeutically, but non-toxic, amount of an anti-parasitic agent in a sustained release form.

20. A method according to Claim 19, wherein the anti-parasitic agent includes a macrocyclic lactone, or an insect growth regulator, or mixtures thereof.

15 21. A method according to Claim 19, wherein the macrocyclic lactone is selected from one or more of the group consisting of ivermectin, moxidectin, eprinomectin and doramectin.

22. A method according to Claim 21, wherein the macrocyclic lactone includes ivermectin.

20 23. A method for the therapeutic or prophylactic treatment of a parasitic condition in an animal (including a human) requiring such treatment, which method includes administering to the animal a sustained release delivery apparatus including a plurality of sustained release mini-implants or pellets; each mini implant or pellet including

25 an anti-parasitic composition including
at least one anti-parasitic agent;
a carrier therefor; and optionally

a sustained release support material; the anti-parasitic composition carried in or on the sustained release support material, when present;

each implant being of insufficient size individually to provide a 5 predetermined desired threshold blood level of anti-parasitic active for treatment of a selected disease indication; and

administering the sustained release delivery apparatus to the animal to be treated.

24. A method according to Claim 25, wherein each mini-implant includes 10 a pharmaceutical active-containing inner layer; and a water impermeable outer layer.

25. A method according to Claim 24, wherein each mini-implant takes the form of an extruded rod bearing a water-impermeable coating thereover.

26. A method according to Claim 23, wherein the mini-implants or pellets 15 are provided in at least two different sizes and provides for the concomitant treatment of ectoparasites and endoparasites.

27. A method according to Claim 26, where the mini-implants or pellets are provided

in a first size which provides a blood level of pharmaceutical active of 20 approximately 1.25 to 3 times the desired threshold blood level for a first relatively short time period; and

in a second size which provides a blood level of pharmaceutical active at or near the desired threshold blood level for a second longer time period.

28. A method according to Claim 23, wherein the animal to be treated is 25 selected from the group consisting of sheep, cattle, horses, pigs, goats, dogs, cats, ferrets, rodents, including mice and rats, birds, including chicken, geese and turkeys, marsupials, fish, primates and reptiles.

29. A method according to Claim 23, wherein the sustained release

delivery apparatus is administered via subcutaneous or intramuscular injection, intranasal insertion or indwelling, intrarectal insertion or indwelling, or oral administration.

30. A method according to Claim 23, wherein the anti-parasitic agent
5 includes a macrocyclic lactone, or an insect growth regulator, or mixtures thereof.

31. A method according to Claim 30, wherein the anti-parasitic agent includes a macrocyclic lactone selected from one or more of the group consisting of ivermectin, moxidectin, eprinomectin and doramectin.

32. A method according to Claim 31, wherein the macrocyclic lactone
10 includes ivermectin.

33. A method according to Claim 23, wherein the anti-parasitic composition further includes a pharmaceutically active component selected from one or more of the group consisting of cytokines, hematopoietic factors, hormones, growth factors, neurotrophic factors, fibroblast growth factor, and
15 hepatocyte proliferation factor; cell adhesion factors; immunosuppressants; enzymes, blood coagulating factors, proteins involved in bone metabolism, vaccines and antibodies.

34. A method according to Claim 23, which method further includes
providing a sustained release kit including
20 a plurality of sustained release mini implants or pellets packaged for delivery in a single treatment;
each mini-implant or pellet including
an anti-parasitic composition including
at least one anti-parasitic agent;
25 a carrier therefor; and optionally
a sustained release support material; the anti-parasitic composition carried in or on the sustained release support material;
each implant being of insufficient size individually to provide a

predetermined desired threshold blood level of anti-parasitic agent for treatment of external parasites; and
administering the mini implants or pellets in a single treatment.

35. A method according to Claim 34, wherein each mini-implant includes
5 a pharmaceutical active-containing inner layer; and
a water impermeable outer layer.

36. A method according to Claim 35, wherein each mini-implant takes the form of an extruded rod bearing a water-impermeable coating thereover.

37. A method according to Claim 34, wherein each mini-implant or
10 pellets is provided in at least two different sizes and provides for the concomitant treatment of ectoparasites and endoparasites.

38. A method according to Claim 37, wherein each the mini-implants or pellets are provided


in a first size which provides a blood level of pharmaceutical active of
15 approximately 1.25 to 3 times the desired threshold blood level for a first relatively short time period; and

in a second size which provides a blood level of pharmaceutical active at or near the desired threshold blood level for a second longer time period.

39. A method according to Claim 34, wherein the plurality of sustained
20 release mini implants or pellets are provided in a biodegradable sheath and administered as a single cartridge via an injector instrument.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/00867

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : A61K 47/14, 31/7048, A61P 33/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) <u>IPC, AS ABOVE</u>		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched <u>AU, IPC, AS ABOVE</u>		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Derwent World Patent Index: controlled/sustained release, mini tablet/implant, parasit*, anthelmint*, rod, capsule		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 140632 B1 (Castex Products Limited) 8 May 1985. See page 2, column 2 line 40, the figures and claims.	14, 15
X	US 5698210 (Richard Levy) 16 December 1997. See column 2 lines 54 to column 6 line 63, the examples and claims.	1, 2, 4
X	EP 990450 A2 (Ivy Animal Health Inc.) 5 April 2000. See paragraphs 8, 9, 16, and the claims.	1-12, 23-26, 28-32, 34-36, 39
Y		1-12, 34-39
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C		<input checked="" type="checkbox"/> See patent family annex
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 16 August 2002	Date of mailing of the international search report 4 SEP 2002	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6283 3929	Authorized officer  K.G. ENGLAND Telephone No : (02) 6283 2292	

INTERNATIONAL SEARCH REPORT

International application No. PCT/AU02/00867

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/37811 A1 (Akzo Nobel N.V.) 31 May 2001 See page 3 line 9 to 24, page 6 line 15 - page 7 line 15, the examples and claims.	1-12, 14-18, 23-26, 28-32, 34-36, 39
Y		1-36
X	WO 01/49269A1 (Shin Poong Pharmaceutical Co, Ltd.) 12 July 2001 See pages 3-5, the examples and claims	14
A	WO 94/27598 A1 (Commonwealth Scientific and Industrial Research Organisation et al) 8 December 1994	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/00867

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
EP	140632	AU	34590/84	NO	844261	NZ	209913
		US	4578263	ZA	8408078		
US	5698210	AU	53640/96	CA	2215377	EP	814659
		WO	9628973	US	6391328	US	6337078
		US	5846553	US	5858384	US	5858386
		US	5885605	US	5902596	US	6001382
		US	6335027	US	6346262	US	6350461
		US	6387386				
EP	990450	AU	48737/99	BR	9904379	US	2001049489
		ZA	9906060				
WO	200137811	AU	200015560				
WO	200149269	AU	200122345				
WO	9427598	AU	67902/94	BR	9406627	CA	2163455
		EP	705101	NZ	266408	US	5840324
		ZA	9403647				
END OF ANNEX							

THIS PAGE BLANK (USPTO)